Review of NICE Technology Appraisal Guidance No.212; Bevacizumab in combination with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine for treating metastatic colorectal cancer

Proposal to move guidance to the static list

The planned date for review of the above guidance is May 2013.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is no new evidence which is likely to lead to a material change in the recommendations made in the original guidance. Consequently we propose that TA212 should be moved to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted. 

May 2013